Advanced search
Publication Cover
Acta Oncologica Volume 54, 2015 - Issue 2
Journal homepage
1,352
Views
9
CrossRef citations to date
0
Altmetric
Colorectal cancer

The ‘real-life’ impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: A large Israeli retrospective cohort study

Ariel HammermanChief Physician's Office, Clalit Health Services Headquarters, Tel-Aviv, IsraelCorrespondence[email protected]
,
Sari Greenberg-DotanChief Physician's Office, Clalit Health Services Headquarters, Tel-Aviv, Israel
,
Erez BattatChief Physician's Office, Clalit Health Services Headquarters, Tel-Aviv, Israel
,
Ilan FeldhamerChief Physician's Office, Clalit Health Services Headquarters, Tel-Aviv, Israel
,
Haim BittermanChief Physician's Office, Clalit Health Services Headquarters, Tel-Aviv, Israel;The Bruce and Ruth Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel
&
Baruch BrennerInstitute of Oncology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Israel;Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Tel-Aviv, Israel
Pages 164-170 | Received 05 May 2014, Accepted 19 Aug 2014, Published online: 28 Oct 2014

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Emerik Osterlund & Bengt Glimelius. (2022) Temporal development in survival, and gender and regional differences in the Swedish population of patients with synchronous and metachronous metastatic colorectal cancer. Acta Oncologica 61:10, pages 1278-1288.
Read now
Bengt Glimelius & Per Pfeiffer. (2018) Do we make progress in elderly patients with metastatic colorectal cancer?. Acta Oncologica 57:11, pages 1422-1426.
Read now
Eetu Heervä, Anu Carpelan, Samu Kurki, Jari Sundström, Heikki Huhtinen, Arto Rantala, Annika Ålgars, Raija Ristamäki, Olli Carpén & Heikki Minn. (2018) Trends in presentation, treatment and survival of 1777 patients with colorectal cancer over a decade: a Biobank study. Acta Oncologica 57:6, pages 735-742.
Read now
Lieke G. E. M. Razenberg, Geert-Jan Creemers, Laurens V. Beerepoot, Allert H. Vos, Agnes J. van de Wouw, Huub A. A. M. Maas & Valery E. P. P. Lemmens. (2016) Age-related systemic treatment and survival of patients with metachronous metastases from colorectal cancer. Acta Oncologica 55:12, pages 1443-1449.
Read now

Articles from other publishers (5)

Bobo Zheng, Xin Wang, Mingtian Wei, Quan Wang, Jiang Li, Liang Bi, Xiangbing Deng & Ziqiang Wang. (2019) First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer 19:1.
Crossref
Matteo Franchi, Sandro Barni, Giovanna Tagliabue, Paolo Ricci, Walter Mazzucco, Rosario Tumino, Antonietta Caputo & Giovanni Corrao. (2019) Effectiveness of First-Line Bevacizumab in Metastatic Colorectal Cancer: The Observational Cohort Study GRETA. The Oncologist 24:3, pages 358-365.
Crossref
Sherif Raouf, Gianfilippo Bertelli, Agnes Ograbek, Polly Field & Irwin Tran. (2019) Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review. Future Oncology 15:5, pages 543-561.
Crossref
Wânia Cristina da Silva, Vânia Eloisa de Araujo, Ellias Magalhães e Abreu Lima, Jessica Barreto Ribeiro dos Santos, Michael Ruberson Ribeiro da Silva, Paulo Henrique Ribeiro Fernandes Almeida, Francisco de Assis Acurcio, Brian Godman, Amanj Kurdi, Mariângela Leal Cherchiglia & Eli Iola Gurgel Andrade. (2018) Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. BioDrugs 32:6, pages 585-606.
Crossref
Kunitoshi Shigeyasu, Yoshinaga Okugawa, Shusuke Toden, C. Richard Boland & Ajay Goel. (2017) Exportin-5 Functions as an Oncogene and a Potential Therapeutic Target in Colorectal Cancer. Clinical Cancer Research 23:5, pages 1312-1322.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.